Cargando…

How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?

Infection is responsible for approximately 25% of all deaths in patients with systemic lupus erythematosus (SLE), making it a leading cause of mortality among patients. Ruiz-Irastorza and colleagues, in a recent issue of Arthritis Research & Therapy, report the clinical predictors of major infec...

Descripción completa

Detalles Bibliográficos
Autor principal: Kamen, Diane L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787187/
https://www.ncbi.nlm.nih.gov/pubmed/19960581
http://dx.doi.org/10.1186/ar2818
_version_ 1782174888015953920
author Kamen, Diane L
author_facet Kamen, Diane L
author_sort Kamen, Diane L
collection PubMed
description Infection is responsible for approximately 25% of all deaths in patients with systemic lupus erythematosus (SLE), making it a leading cause of mortality among patients. Ruiz-Irastorza and colleagues, in a recent issue of Arthritis Research & Therapy, report the clinical predictors of major infections found in a prospective study of patients with SLE. Similar patterns of infection and pathogens as reported in previous studies were seen; what is striking, however, was the protective effect seen with anti-malarial use. Many infections in patients with SLE could be prevented with timely vaccinations, reducing exposure to contagious contacts, screening for latent infections, minimizing exposure to corticosteroids, targeted prophylaxis for high risk patients, and, unless contraindicated, anti-malarial therapy as standard of care.
format Text
id pubmed-2787187
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27871872009-12-02 How can we reduce the risk of serious infection for patients with systemic lupus erythematosus? Kamen, Diane L Arthritis Res Ther Editorial Infection is responsible for approximately 25% of all deaths in patients with systemic lupus erythematosus (SLE), making it a leading cause of mortality among patients. Ruiz-Irastorza and colleagues, in a recent issue of Arthritis Research & Therapy, report the clinical predictors of major infections found in a prospective study of patients with SLE. Similar patterns of infection and pathogens as reported in previous studies were seen; what is striking, however, was the protective effect seen with anti-malarial use. Many infections in patients with SLE could be prevented with timely vaccinations, reducing exposure to contagious contacts, screening for latent infections, minimizing exposure to corticosteroids, targeted prophylaxis for high risk patients, and, unless contraindicated, anti-malarial therapy as standard of care. BioMed Central 2009 2009-10-28 /pmc/articles/PMC2787187/ /pubmed/19960581 http://dx.doi.org/10.1186/ar2818 Text en Copyright ©2009 BioMed Central Ltd
spellingShingle Editorial
Kamen, Diane L
How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?
title How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?
title_full How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?
title_fullStr How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?
title_full_unstemmed How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?
title_short How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?
title_sort how can we reduce the risk of serious infection for patients with systemic lupus erythematosus?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787187/
https://www.ncbi.nlm.nih.gov/pubmed/19960581
http://dx.doi.org/10.1186/ar2818
work_keys_str_mv AT kamendianel howcanwereducetheriskofseriousinfectionforpatientswithsystemiclupuserythematosus